CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.